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ABSTRACT 1 
Background: Low glycemic index diets have demonstrated health benefits associated with a 2 
reduced risk of developing type 2 diabetes.  3 
Objectives: We tested whether pomegranate polyphenols could lower the glycemic response 4 
of a high glycemic index food when consumed together, and the mechanism by which this 5 
might occur.  6 
Design: We compared the acute effect of a pomegranate juice and a polyphenol-rich extract 7 
from pomegranate (supplement) on the bread-derived post-prandial blood glucose 8 
concentration in 2 randomized, crossover, controlled studies (double-blinded for the 9 
supplements), each on 16 healthy volunteers. An additional randomized, crossover, controlled 10 
study on 16 volunteers consuming constituent fruit acids in a pH balanced solution (same pH 11 
as pomegranate) and bread was conducted to determine any contributions to post-prandial 12 
responses caused by acidic beverages. 13 
Results: As primary outcome, the incremental area under the curve for bread-derived blood 14 
glucose (-33.1 ± 18.1 %, p = 0.000005) and peak blood glucose (25.4 ± 19.3%, p = 0.0004) 15 
were attenuated by pomegranate juice, compared to a control solution containing equivalent 16 
amount of sugars. In contrast, the pomegranate supplement, or a solution containing the malic 17 
and citric acid components of the juice, were ineffective. The pomegranate polyphenol 18 
punicalagin was a very effective inhibitor of human D-amylase in vitro, comparable to the 19 
drug acarbose. Neither the pomegranate extract, nor the individual component polyphenols, 20 
inhibited 14C-D-glucose transport across differentiated Caco-2-TC7 cell monolayers, but 21 
inhibited uptake of 14C-glucose into Xenopus oocytes expressing the human sugar transporter 22 
GLUT2. Further, some of the predicted pomegranate gut microbiota metabolites modulated 23 
14C-D-glucose and 14C-deoxy-D-glucose uptake into hepatic HepG2 cells.  24 
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Conclusions: These data indicate that pomegranate polyphenols, when present in a beverage, 25 
but not in a supplement, can reduce the post-prandial glycemic response of bread, while 26 
microbial metabolites from pomegranate polyphenols exhibit the potential to further 27 
modulate sugar metabolism much later in the postprandial period. 28 
29 
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INTRODUCTION 30 
Post-prandial glycemic control and levels of sugar in the diet are both topics of current 31 
concern and controversy. While the glycemic index was introduced many decades ago, its 32 
relevance to health maintenance and diseases such as the metabolic syndrome, diabetes and 33 
obesity, are only now being fully recognised through reviews and meta-analyses (1-3). 34 
Postprandial glucose naturally rises following digestion of rapidly hydrolyzable 35 
carbohydrates, such as soluble starch, some forms of cooked starch, or from soluble sugars 36 
present in the food such as glucose, fructose and sucrose. After processing by salivary and 37 
pancreatic D-amylase, followed by intestinal brush border maltase/glucoamylase and 38 
sucrase/isomaltase, the product glucose is rapidly absorbed through intestinal sugar 39 
transporters GLUT2 and SGLT1 across the enterocytes, whereas the product fructose is 40 
absorbed through GLUT2 and GLUT5.  41 
There are several reports of human intervention studies on the effect of pomegranate juice on 42 
health biomarkers. Systolic and diastolic blood pressure was reduced in hypertensive patients 43 
after consumption for 2 weeks (4), in healthy adults after 4 weeks (5), and in slightly 44 
overweight but otherwise healthy adults after 2 and 4 weeks (6). None of these studies 45 
however showed a concomitant effect on pulse wave velocity or on flow mediated dilation, 46 
while the latter study showed a decrease in fasting plasma insulin. In contrast, in another 47 
study on 20 obese adults, pomegranate juice did not modify insulin secretion and sensitivity 48 
(7). In hypertensive patients, part of the decrease in blood pressure in vivo was ascribed to a 49 
decrease in angiotensin converting enzyme (ACE) activity (8).  50 
Pomegranate is uniquely rich in punicalagin and punicalin (Figure 1), and these polyphenols 51 
are responsible for some of the sensory characteristics of the juice. We hypothesized that one 52 
possible complementary mechanism to the effects on pomegranate consumption could be on 53 
intestinal sugar absorption through inhibition of carbohydrate-digesting enzymes and direct 54 
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interactions with sugar transporters, ultimately affecting post prandial blood glucose 55 
concentrations. The literature in this area is very sparse. In one report, pomegranate juice did 56 
not inhibit pig D-amylase nor rat intestinal sucrase (9) while punicalagin, punicalin and 57 
HOODJLFDFLGZHDNO\LQKLELWHGUDWLQWHVWLQDO³D-JOXFRVLGDVH´EXWWKLVZDVRQO\DVVHVVHGZLWK58 
an artificial p-nitrophenol substrate which renders the obtained results irrelevant for 59 
interpretation in the in vivo setting. As part of the same study, pig D-amylase acting on 60 
soluble potato starch was only weakly inhibited (10). In another report on the effect of 61 
pomegranate tannins on glucosidase activities, the enzymes used were from Bacillus 62 
licheniformis (D-amylase on potato starch) and from Aspergillus niger (glucoamylase on 63 
maltose), bearing no similarity or relevance to the human digestive system (11). We have 64 
therefore revisited the hypothesis that pomegranate juice may beneficially modulate post-65 
prandial responses through inhibition of carbohydrate digesting enzymes by employing 66 
suitable in vitro enzyme assays and also assessing the effect on sugar transport.  67 
 68 
69 
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SUBJECTS AND METHODS 70 
Materials 71 
The tested extract (supplement) was prepared from pressed pomegranate (Punica granatum 72 
var. Mollar) during pomegranate juice processing. It contains husk, internal membranes and 73 
remaining seed from which juice has been removed. When given in very high doses to rats, 74 
no toxic effects were observed (12), and when given to volunteers for 3 weeks, showed no 75 
undesirable side effects and even showed an improvement in various blood cholesterol 76 
biomarkers in urolithin-metabotype-B volunteers (13). Pure, 100 % organic pomegranate 77 
MXLFHZDVXVHGIRUWKHVWXG\³%LRQD´+HDOWK\6XSSOLHV8.www.healthysupplies.co.uk). 78 
Sodium bicarbonate used to control the pH of the fruit acid solution was from Health Leads 79 
UK (www.healthleadsuk.com). Citric acid was from Minerals-Water, Rainham, UK, and the 80 
malic acid was from Bartek Ingredients Inc, Stoney Creek, Canada. Human salivary D-81 
amylase, rat intestine extract (acetone-extracted protein-rich powder), sucrose, maltose and 82 
glucose were from Sigma-Aldrich (Dorset, UK). Ellagic acid, punicalagin (isomeric mixture 83 
of punicalagin A and B) and punicalin (mixture of A and B) were from Phytolab 84 
(Vestenbergsgreuth, Germany). Urolithin metabolites and the corresponding glucuronic acid 85 
conjugates were chemically synthetized by Villapharma Research S.L. (Fuente Alamo, 86 
Spain) (14). Malic acid and citric acid ion chromatography standards were purchased from 87 
Sigma-Aldrich (Dorset, UK). 88 
 89 
Pomegranate analysis 90 
Juice samples were directly injected after centrifugation and filtration on a reversed phase 91 
column on an Agilent 1200 HPLC system equipped with a photodiode array detector and an 92 
ion-trap mass spectrometer detector using water-formic acid and acetonitrile as solvents (15). 93 
For analysis, pomegranate extract powder from the capsules was first dissolved in methanol-94 
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DMSO (1:1; v/v). Punicalin and punicalagin were quantified at 360 nm based on a calibration 95 
curve for punicalagin, while their derivatives and other ellagitannins were relative to a 96 
calibration curve for ellagic acid. Results are expressed as mean values of three replicates and 97 
are shown in Table 1. Sugar quantification was performed using a Shimadzu HPLC 98 
instrument equipped with a DGU-20 A5 degasser, a LC-20 AD XR pump system, a SIL-20 99 
AC XR auto sampler, column oven, a diode array detector system (SPD-M20A) and a 100 
Shimadzu ELSD-LTII low temperature evaporative light scattering detector as described 101 
previously (16). Quantitation was carried out based on standard curves with concentrations 102 
up to 10 mg/mL (r2 > 0.98). Data from the sugar analysis allowed balancing of the control 103 
samples for glucose and fructose naturally present in the pomegranate juice. Fructose and 104 
glucose contents were 51.8 ± 0.1 and 54.6 ± 0.1 g/L for the juice, and 0.0066 and 0.0083 105 
mg/mg for the extract, respectively. No sucrose was detected in pomegranate juice as 106 
expected (17). Analysis of malic and citric acids in pomegranate juice was conducted by ion 107 
chromatography on a reagent-free high pressure Ion Chromatography Dionex Integrion 108 
system (RFIC, HPIC) equipped with a conductivity detector (ECD), an electrolytic eluent 109 
generator to automatically produce an isocratic potassium hydroxide eluent and an AS-AP 110 
autosampler (Thermo Scientific, UK). The AS-AP was equipped with an external injection 111 
ORRSȝODQGZDVUXQ in full-injection-loop mode onto an IonPac AG11-ȝPJXDUG112 
column (2 x 50 mm) attached to an IonPac AS11-ȝPDQDO\WLFDOFROXPQîPP113 
(Thermo Scientific, UK) at a flow rate of 0.38 ml/min. The column compartment was held at 114 
35 C and the ECD compartment at 20 C. The optimized analytical run gradient started at 1 115 
mM KOH, was held isocratically for 10.7 min, and then increased linearly to 15 mM from 116 
10.7 to 24 min, 30 mM after 13.3 min and 60 mM after a further 13.3 min. An 8 min isocratic 117 
60 mM KOH period was included to wash out any strongly adsorbing components, followed 118 
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by re-equilibration to 1 mM for 7min. Malic acid eluted at 27.96 min and citric acid at 43.57 119 
min. 120 
 121 
Subjects 122 
Healthy individuals free of symptomatic disease, aged between 18 and 75, not diabetic, not 123 
pregnant or lactating, not on a special diet (weight loss or fruits supplements) or on long term 124 
prescribed medication with fasting blood glucose between 3.9 and 5.9 mmol/L were recruited 125 
at the School of Food Science and Nutrition, University of Leeds, UK by means of local 126 
poster adverts. Volunteers expressing interest were screened for fasting blood glucose, and 127 
upon meeting all eligibility criteria, they provided written informed consent and were 128 
allocated codes by the researcher responsible for intervention studies which were used in the 129 
allocation of the order of interventions. All meals consisted of 109.0 ± 1.2 g white bread (50 130 
g available carbohydrate as analyzed by the method of Englyst (18)). Some individuals could 131 
have participated in more than one of the studies reported here. 132 
 133 
Design and intervention  134 
A total of 16 healthy volunteers were recruited for the pomegranate supplements study from 135 
June 2015. The volunteers were aged 26 ± 6 y with BMI of 23 ± 2 kg/m2 and fasting blood 136 
glucose of 4.7 ± 0.4 mmol/l. The study intervention was randomized, controlled, double-137 
blinded (HNS conducted the intervention and recruited volunteers; blinding of capsules was 138 
done by a code given and stored by a third party) and with a crossover design. Each volunteer 139 
conducted three visits; receiving bread together with reference (400 mg placebo capsules 140 
(cellulose)), test dose 1 (200 mg placebo and 200 mg pomegranate supplement) and test dose 141 
2 (400 mg pomegranate supplement) together with 200 ml water. Sugars present in the 142 
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pomegranate capsules were negligible in terms of human consumption. Bread was consumed 143 
5 min after taking the supplements to allow for dissolution in the stomach. 144 
The 16 volunteers for the pomegranate juice study were recruited from November 2015 until 145 
March 2016 and were aged 31 ± 5 y with BMI of 23 ± 3 kg/m2 and fasting blood glucose 146 
concentration of 4.7 ± 0.5 mmol/L and were recruited separately based on the same eligibility 147 
criteria at a different time. The study protocol was un-blinded due to the nature of the test 148 
meal. Each volunteer attended four visits, two where reference meals (200 ml water with 149 
balancing sugars and bread) were consumed and another two at which test meals of the same 150 
dose (200 ml pure pomegranate juice and bread) were ingested. The reference meal included 151 
10.9 g fructose and 10.3 g glucose dissolved in 200 ml water to standardize the amounts of 152 
sugars present in the pomegranate juice. 153 
The 16 volunteers for testing the acid solution, equivalent to the malic acid, citric acid and 154 
potassium content of pomegranate juice, were recruited from October 2016 until August 2017 155 
and were aged 33 ± 9 years with BMI of 25.0 ± 3.8 kg/m2, fasting blood glucose 156 
concentration of 4.9 ± 0.4 mM and were recruited separately based on the same eligibility 157 
criteria at a different time. The study protocol was un-blinded due to the nature of the test 158 
meal. The volunteers consumed 109 g bread as above, together with 200 ml water containing 159 
3.82 g citric acid and 0.118 g malic acid, adjusted to pH 3.2 with sodium bicarbonate, 160 
compared to 200 ml tap water as control. Each volunteer attended, in randomized order, for 161 
the control and for the test.  162 
For all studies, following a baseline glucose measurement, the volunteers consumed the meal. 163 
The timer was started upon the first bite or sip and the whole meal was consumed in less than 164 
15 min. The primary outcome was blood glucose concentration. Blood glucose measurements 165 
were repeated at 15, 30, 45, 60, 90, 120, 150 and 180 min post-consumption and recorded 166 
immediately. For all studies, the meals were administered in a randomized pattern and a 167 
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glucometer was used to instantly measure the blood glucose from a finger-prick for each time 168 
point. The glucometer showed excellent agreement (within 0.1 mM) with the glucose 169 
hexokinase assay reported previously (19). There was no apparent harm nor side effects 170 
incurred during the consumption of the meals, or by the finger prick, and no adverse effects 171 
were observed. The study protocols were approved by the University of Leeds, Faculties of 172 
Mathematics and Physical Sciences and Engineering Ethics Committee (MEEC 14-029,  173 
MEEC 12-037 and MEEC15-044a)  and the protocols were registered with 174 
ClinicalTrials.gov, ID numbers NCT02486978, NCT02624609 and NCT03242876 for the 175 
pomegranate supplements, pomegranate juice and fruit acid studies respectively. All 176 
interventions were conducted by the researcher, HNS, responsible for intervention studies.  177 
 178 
Enzyme inhibition assays in vitro 179 
The effect of pomegranate extract on D-amylase was tested in vitro as previously described 180 
using a fully validated and characterised assay procedure using amylose, the naturally-181 
occurring and unbranched component of starch (20). Inhibition of rat intestinal brush border 182 
Į-glucosidase was determined by measuring the hydrolysis of maltose into glucose using a 183 
hexokinase-linked assay (19). 184 
 185 
Glucose transport  186 
Caco-2/TC7 cells were a kind gift from Prof. Monique Rousset, (INSERM, France). For 187 
transport experiments, cells were seeded on 6-well Transwell plates (Corning 3412, Appleton 188 
Woods, Birmingham, UK) at a density of 6.43 x 104 cells/cm2 until full differentiation of the 189 
monolayer (21 - GD\VLQ'XOEHFFR¶V0RGLILHG(DJOH¶V0HGLXPP0'0(0190 
supplemented with 20% (v/v) Fetal Bovine Serum (FBS), 100 U/ml penicillin, 0.1 mg/ml 191 
streptomycin at 37°C with 10% CO2 in a humidified atmosphere. All cell culture reagents 192 
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were from Sigma (Sigma Aldrich, Gillingham, UK). On or after 22 d studies were initiated 193 
and cells in both compartments were washed and incubated with transport buffer A (HEPES, 194 
20 mM; NaCl, 137 mM; KCl, 4.7 mM; CaCl2 1.8 mM, MgSO4 1.2 mM; adjusted to pH 7.4 195 
using NaOH, 1 M) for 30 min. Transepithelial electrical resistance (TEER) measurements 196 
were recorded using a Millicell ERS volt-ohm meter (Millipore Ltd, Watford, UK). The 197 
buffer was aspirated and the relevant test solution at pH 7.4 was added apically with 5 mM 198 
glucose and 0.1 µCi/ well D-[U-14C] glucose. The pomegranate extract naturally contained 199 
0.46 mM glucose and 0.37 mM fructose when made up in a solution of DMSO; 0.37 mM 200 
fructose did not affect glucose transport compared to 5 mM glucose when tested in the same 201 
set-up (data not shown). Plates were incubated for 30 min and all solutions were collected 202 
and mixed with 5 ml of scintillation liquid (Gold Star, Meridian Biotechnologies, Surrey, 203 
UK) for radioactivity measurements with a Packard 1900 TR Liquid Scintillation Analyser.    204 
 
205 
D-[U-14C]-glucose and [U-14C]-deoxy-D-glucose uptake by HepG2 cells 206 
Uptake of D-[U-14C] glucose and deoxy-D-glucose by HepG2 cells was performed as fully 207 
described and validated previously (22). Uptake of D-[U-14C]-glucose into Xenopus oocytes 208 
expressing human GLUT2 was performed as described and optimized previously (23). 209 
 210 
Statistical analysis 211 
All three intervention trials were designed to have 90% power to detect a clinical difference 212 
of 15% IAUC between the test and reference meal (D = 0.05). A total of 15 volunteers were 213 
required for the reference and test meals to achieve the above power and clinical difference. 214 
Thus a minimum of 15 participants were recruited for each study as each participant was a 215 
control of themselves. The trapezoidal rule was used to calculate the incremental area under 216 
the glucose curves (IAUC) for each volunteer. Data analysis was performed by the two tailed 217 
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paired t-test and confirmed with the one factor repeated measures analysis of variance 218 
(ANOVA) by SPSS v24 (IBM). Comparisons between control and treatment in D-[U-14C]-219 
glucose and [U-14C]-deoxy-D-glucose uptake cell experiments was carried out by 220 
independent samples two tailed 6WXGHQW¶Vt-test between control and treatment and the 2-221 
tailed values were adjusted for multiple comparisons with the Bonferroni correction. D-[U-222 
14C] glucose uptake into Xenopus oocytes expressing human GLUT2 was normalized against 223 
water injected oocytes for each condition. Two-tailed KRPRVFHGDVWLF6WXGHQW¶Vt-test was 224 
used to assess significance between uptake with and without varying concentrations of 225 
pomegranatH)RUĮ-amylase assays, all IC50 values are given as mean ± standard deviation 226 
from triplicates of 3 independent assays obtained by regression.  227 
228 
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RESULTS 229 
,QKLELWLRQRIĮ-DP\ODVHDQGĮ-glucosidase activities in vitro 230 
7KHGLVVROYHGSRPHJUDQDWHH[WUDFWLQKLELWHGKXPDQĮ-amylase and rat intestinal brush border 231 
maltase/sucrase activities in vitro (Figure 2, Table 2). Of the individual components, 232 
SXQLFDODJLQZDVDYHU\HIIHFWLYHLQKLELWRURIĮ-amylase, but ellagic acid and punicalin were 233 
PXFKZHDNHU7DEOH7KHLQKLELWLRQRIĮ-amylase by punicalagin exhibited a Ki value of 234 
10.1 ± 0.6 PM with kinetically competitive inhibition.  235 
 236 
Inhibition of D-[U-14C]-glucose transport across Caco-2 cell monolayers and into 237 
Xenopus oocytes expressing GLUT2 238 
To test if pomegranate extract, juice or its constituent polyphenols have the potential to affect 239 
intestinal glucose transport, we employed differentiated Caco-2 cell monolayers which 240 
express the relevant transporters involved in glucose transport (24) and have been well 241 
characterized and reported to be highly suitable for this purpose (25). All extracts and 242 
individual compounds showed no inhibition of D-[U-14C]-glucose transport (Figure 2) when 243 
tested at millimolar concentrations of glucose. At lower concentrations of glucose, 244 
pomegranate inhibited the uptake of D-[U-14C]-glucose by Xenopus oocytes expressing 245 
GLUT2 (Figure 2). 246 
 247 
Effect of pomegranate juice on bread-derived post-prandial blood glucose  248 
Based on the above in vitro data, we then tested whether the observed inhibition would be 249 
sufficient to affect the post-prandial response of bread as an added cooked starch source. A 250 
randomized, controlled, crossover intervention was conducted on 16 healthy volunteers, and 251 
the control and treatment were both performed twice on the same volunteers, making a total 252 
of 4 visits for each volunteer (Figure 3). There was a significant difference for both the 253 
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IAUC and peak glucose concentration between the reference and test meal (Figure 4 and 254 
Table 3). Pomegranate juice brought about a decrease in the glucose IAUC of -33.1±18.1 % 255 
(p = 0.000005; n = 16) and in peak glucose concentration (-25.4 ± 19.3 %, p = 0.0004) When 256 
analysed separately, no significant difference was observed between the two control meals, 257 
nor between the two test meals (p>0.05). 258 
 259 
Effect of a pomegranate polyphenol supplement on bread-derived post-prandial blood 260 
glucose 261 
Since pomegranate juice attenuated post-prandial blood glucose concentrations, we then 262 
tested if the constituent extracted polyphenols could also have the same function when given 263 
as a supplement in a capsule. Qualitatively, the juice and extract contained the same 264 
polyphenols, but the absolute amounts were different. The amount of our proposed most 265 
³DFWLYH´FRPSRQHQWIRUGLJHVWLYHHQ]\PHLQKLELWLRQSXQLFDODJLQZDVa-fold higher in the 266 
capsules compared to the juice (Table 1). A randomized, placebo-controlled, double blinded, 267 
two-dose, crossover intervention on 16 healthy volunteers was performed (Figure 3). There 268 
was no significant difference (p > 0.05) between IAUC of the reference, low dose and high 269 
dose of the interventions. The peak glucose concentrations were also not significantly 270 
different (p > 0.05) (Figure 4 and Table 3). 271 
 272 
Effect of pomegranate fruit acids on bread-derived post-prandial blood glucose 273 
Pomegranate is a somewhat acidic beverage since it contains constituent fruit acids. It has 274 
been reported that vinegar, which is highly acidic, reduced the glycemic response of a bagel 275 
by 20% (26), malic acid was proposed to reduce glycemic responses when present in various 276 
fruit and vegetables (although importantly the polyphenol content was not considered) (27), 277 
and addition of organic acids, as in sourdough bread, may somewhat suppress the glycemic 278 
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response (28). We therefore tested whether any changes in blood glucose could have been 279 
augmented by the acidity (due to malic acid and citric acid) of the pomegranate juice. The 280 
(measured) pH of the pomegranate juice used was 3.2. Healthy volunteers (n = 16) consumed 281 
200 ml of a solution of malic and citric acid (at the same concentration as measured in 282 
pomegranate juice) balanced to pH 3.2 with sodium bicarbonate together with bread. There 283 
was no significant effect on post-prandial glycemia when compared to a water control 284 
consumed with bread (Table 3), indicating that these components were unlikely to contribute 285 
to the effect of pomegranate juice on post-prandial glycemia.  286 
 287 
Further sugar metabolism by hepatic uptake 288 
Since the liver plays a major role in glucose metabolism after uptake by the gut, we also 289 
tested whether colonic microbiota metabolites derived from pomegranate polyphenols could 290 
affect glucose uptake into HepG2 cells as a model for the post-prandial disposition of glucose 291 
into hepatocytes (22). Pomegranate polyphenols are predominantly absorbed in the form of 292 
urolithins and ellagic acid after conversion by gut microbiota. Some of the urolithins and 293 
their conjugates modulated cellular uptake of D-[U-14C]-glucose in HepG2 cells (Figure 5). 294 
UroA inhibited, whereas UroC and UroD stimulated, uptake of the non-metabolizable 295 
glucose analog, [U-14C]-deoxy-D-glucose, indicating an effect on transport. On the other 296 
hand, UroB-glucuronide, UroA, UroC and UroD decreased the cellular uptake of D-[U-14C]-297 
glucose, indicating a potential effect on glucose metabolism.  298 
299 
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Discussion 300 
 301 
The role of supplements and extracts in support of a healthy diet remains controversial, and 302 
much of the dietary advice available from government agencies is related to food and diets. 303 
Here we show that pomegranate juice, rich in polyphenols, can reduce post-prandial blood 304 
glucose spikes when consumed together with bread as a digestible carbohydrate source. The 305 
effect is quite substantial, since the area under the glucose curve is reduced by a third, with 306 
high significance. Based on in vitro data, the mechanism of action is inhibition of D-amylase 307 
by the polyphenolic constituent, punicalagin, which is more potent than punicalin and ellagic 308 
acid, and possibly inhibition of glucose transport at low glucose concentrations. However, a 309 
polyphenol-rich extract from pomegranate, when co-consumed with bread, did not exhibit the 310 
same effect. Since these capsules contained ~4-fold higher level of the putative main active 311 
component, punicalagin, we propose that the lack of effectiveness could be due to insufficient 312 
mixing in the stomach and intestine with the bread, or inefficient solubilization in the 313 
stomach and small intestine. The capsule material itself dissolved rapidly in 5 minutes under 314 
conditions mimicking the stomach (data not shown).  315 
 316 
The effect of the juice is comparable to the non-absorbed drug acarbose, which is 317 
administered to diabetic patients to limit post-prandial glucose excursions. When 50 mg 318 
acarbose was given in 3 doses before breakfast, lunch and dinner to healthy volunteers, the 319 
average reduction in post-prandial glucose was also about one third (29), comparable to the 320 
study on pomegranate juice reported here. Acarbose reduces the risk of cardiovascular 321 
disease and hypertension in patients with impaired glucose tolerance and with type 2 diabetes 322 
(30, 31). The digestion of bread to glucose and intestinal absorption of glucose require at 323 
least 3 biochemical steps (Figure 6), the first of which is D-amylase, followed by conversion 324 
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of the product into glucose by brush border maltase activity. Although pomegranate extract 325 
was mildly effective at inhibiting maltase activity, this effect was not due to the constituent 326 
polyphenols (punicalagin, punicalin nor ellagic acid, Table 2). The third step is glucose 327 
absorption across the intestine which has been modelled using differentiated Caco-2 cell 328 
monolayers, and by human GLUT2 expression in Xenopus oocytes. Neither pomegranate 329 
juice nor its constituent polyphenols were able to affect glucose transport across Caco-2 cells, 330 
but could interact with GLUT2 in Xenopus oocytes. These lines of evidence point to 331 
inhibition of D-amylase as the main mechanism of action, with a potential contribution by 332 
interactions with GLUT2. The IC50 YDOXHIRULQKLELWLRQRIKXPDQVDOLYDU\Į-amylase on 333 
DP\ORVHE\SXQLFDODJLQZDVPHDVXUHGDVȝ0ZKLFKLVFRPSDUDEOHWRWKDWUHSRUWHG334 
SUHYLRXVO\IRUDFDUERVHȝ0XQGHUWKHVDPHFRQGLWLRQV(23). 335 
In other studies, pomegranate consumption was shown to affect sugar metabolism in different 336 
ways by alternative mechanisms. In patients with type 2 diabetes, chronic pomegranate juice 337 
consumption led to reduced fasting glucose concentrations in those subjects with blood 338 
glucose levels between 7.1 and 8.7 mmol/L, compared to patients with higher levels (32). 339 
Pomegranate juice consumption also decreased plasma malondialdehyde and carbonyl levels 340 
after exercise (33) and plasma malondialdehyde in type 2 diabetes patients (34), but the 341 
relevance of these markers for disease risk is controversial, see for example (35). The role of 342 
post-prandial glucose in disease risk is becoming appreciated, and in a review of 45 relevant 343 
publications, lower glycemic index (GI) diets reduced both fasting blood glucose and 344 
glycated proteins. These effects were greater in persons with poor fasting blood glucose 345 
control (2).  346 
The intestinal fate and absorption of pomegranate polyphenols has been described. 347 
Ellagitannins such as punicalagin and punicalin in pomegranate are readily hydrolysed to 348 
ellagic acid, further converted to urolithins by the gut microbiota, and conjugated by 349 
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intestinal or hepatic phase II metabolism. The urinary level of urolithin A glucuronide was 350 
not significantly different after consumption of pomegranate juice, a pomegranate polyphenol 351 
liquid extract and a pomegranate polyphenol powder extract (36), demonstrating that 352 
pomegranate polyphenols as supplements are ultimately solubilised in the gastrointestinal 353 
tract at least by the time they reach the colon. We show for the first time that these 354 
metabolites have the potential ability to further modulate sugar metabolism, as assessed here 355 
using the HepG2 cell model, during the late post-prandial period (3-6 h). Urolithins C and D 356 
stimulated deoxy-D-glucose uptake and modulated glucose metabolism, urolithin B 357 
glucuronide modulated glucose metabolism, and urolithin A inhibited deoxy-D-glucose 358 
uptake and modulated glucose metabolism. These data show that pomegranate polyphenols 359 
have the potential to further influence glucose metabolism and is a subject worthy of future 360 
study. The concentrations used are within the same order of magnitude to those found in 361 
some individuals in vivo, although the concentrations in plasma and urine are subject to 362 
substantial inter-individual variation, where individuals can be classed as producers or non-363 
producers for some types of urolithins (13). These differences arise from the resident 364 
microflora of consumers further highlighting underlying potential benefits in different groups 365 
(37), and could provide a mechanistic rationale for the chronic effect of pomegranate juice on 366 
fasting blood glucose levels seen previously (32).   367 
 368 
In conclusion, we have shown that pomegranate polyphenols, when present in a beverage, but 369 
not a supplement, can reduce the acute post-prandial glycemic response of bread, and we 370 
propose that this is primarily due to the ability of punicalagin to inhibit D-amylase. Further, 371 
pomegranate polyphenol microbial metabolites may modulate sugar metabolism following 372 
the acute postprandial period. 373 
 374 
375 
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TABLE 1.  
Composition of pomegranate juice and extracts1. 
 Amount in juice2 Amount in capsules 
 mg/L Per dose (mg) mg/g Per high dose3 capsule (mg) 
Punicalin 357.3 ± 1.1 71.5 6 2.4 
Punicalagin 61.9 ± 0.6 12.4 121 48 
Ellagic acid hexose   14.2 ± 0.1 2.8 5.9 2.4 
Ellagic acid  24.0 ± 0.3 4.8 101 40.4 
Malic acid4 595.4 ± 24.5 119.1 0 0 
Citric acid4 19095 ± 570 3819 0 0 
Glucose 51800 ± 1000 10400 8.3 3.3 
Fructose  54700 ± 900 10900 6.6 2.6 
 
1Juice and extracts were analyzed by HPLC relative to authentic standards.  
2For juice (200 ml), mean and standard deviation shown, n = 3. 
3The high dose contained 400 mg of extract, double that of the low dose.  
4Analysis carried out by HPIC (see methods section) 
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TABLE 2  
Inhibition of digestive enzymes by pure pomegranate polyphenols compared to acarbose.  
 IC501 (mg/ml) IC50 (µM) Inhibition (%) at 200 µM 
Enzyme Pomegranate extract Acarbose Punicalagin Punicalin2 Ellagic 
acid  
D-Amylase  0.06 ± 0.01  3.5 ± 0.2 9.0 ± 1.03 29.9 ± 0.9  26.5 ± 0.5 
Maltase 1.0 ± 0.1 0.43 ± 0.1 NI4  NI  NI  
Sucrase 1.2 ± 0.3 12 ± 2 NI  NI  NI  
 
1Experimental IC50 YDOXHVIRUKXPDQVDOLYDU\Į-DP\ODVHXVLQJDP\ORVHDVVXEVWUDWHDQGUDWĮ-
glucosidase using maltose and sucrose as substrates for pomegranate extract and its major 
polyphenols (n = 3).  
2A further increase in the concentration of punicalin and ellagic acid to 1000 PM did not 
significantly increase the inhibition obtained at 200 µM.  
3A Ki value of 10.1 ± 0.6 PM was measured for punicalagin on D-amylase at different 
concentrations of amylose, and calculated according to (19).  
4NI is no inhibition at 200 µM compared to acarbose as positive control.  
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TABLE 3.  
Post-prandial blood glucose after a single dose of bread together with pomegranate juice, 
supplements or fruits acids. 
Intervention study Test meal IAUC1 (mmol/L.min) Peak glucose1 (mmol/L) 
Bread (109 g) with 
pomegranate 
supplements 
Placebo 
 
159 ± 57 6.8 ± 1.0 
Capsule (200 mg 
extract) 
 
183 ± 87 6.8 ± 0.8 
Capsule (400 mg 
extract) 
184 ± 61 6.7 ± 0.9 
Bread (109 g) with 
pomegranate juice 
 
 
200 ml solution of 
balancing sugars 
 
199 ± 64a 7.7 ± 0.9c 
200 ml juice 134 ± 62b 6.8 ± 1.0d 
Bread (109 g) with 
malic acid and citric 
acid pH 3.2 
200 ml water 
 
200 ml of test 
solution 
152 ± 56 
 
177 ± 71 
 
7.2 ± 0.8 
 
7.3 ± 1.0 
 
 
1Average IAUC and peak glucose concentrations after consumption of indicated foods and 
beverages. Bread with pomegranate supplements at 2 doses was compared to placebo capsules. 
Bread with pomegranate juice was compared to water containing balancing sugars as control. All 
studies were a crossover design with 16 participants. Values are mean ± standard deviation 
where different superscript letters indicate significant difference (p<0.01) using student t-test and 
confirmed by ANOVA (p value).  
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FIGURE 1. Chemical structures of pomegranate polyphenols  
 
FIGURE 2. Inhibition of sugar transport and digestive enzyme by pomegranate extract and 
FRQVWLWXHQWFRPSRXQGV,QKLELWLRQRIKXPDQVDOLYDU\Į-DP\ODVHŶXVLQJDP\ORVHDVVXEVWUDWH
DQGUDWLQWHVWLQDOJOXFRVLGDVHXVLQJPDOWRVHƔDQGVXFURVHŸDVVXEVWUDWHE\SRPHJUDQate 
extract (panel A). Inhibition of apical to basolateral transport of D-[U-14C-]-glucose across 
differentiated monolayers of Caco-2 TC7 cells (12-30 replicates per data point ± SD, panel B) 
and uptake of D-[U-14C-]-glucose into Xenopus oocytes expressing the human glucose 
transporter GLUT2 (6 replicates of 3 oocytes expressing GLUT2, normalized to water controls, 
± SEM (panel C) by pomegranate extract. Inhibition of apical to basolateral transport of D-[U-
14C-]-glucose across differentiated monolayers of Caco-2 TC7 cells by pomegranate polyphenols 
is shown in Panel D for punicalagin ( ŸSDQHO(IRUSXQLFDOLQŶDQGSDQHO)IRUHOODJLFDFLG
Ƈ6 replicates per data point ± SD, control samples contained the equivalent amount of 
DMSO). Significant differences to the control are shown (***, p<0.001).  
 
FIGURE 3. Participant flow diagrams for the intervention on pomegranate juice (Panel A), on 
constituent fruit acids (Panel B) and on pomegranate extract (Panel C). Simple randomization 
was used to determine the different groups (test or control), and block randomization was used to 
randomize participants into groups to ensure equal number of participants in each group. The 
four different sequences obtained were then allocated to participant codes by the principal 
investigator by pre-assigning the order of the meals to each code, which then determined the 
order of intervention. 
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FIGURE 4. Post-prandial blood glucose concentrations after consumption of bread with 
pomegUDQDWHMXLFHRUH[WUDFW*OXFRVHFXUYHVDIWHUFRQVXPSWLRQRIFRQWUROżƑDQG
SRPHJUDQDWHMXLFHŶƔZLWKEUHDGYROXQWHHUVSDQHO$,QGLYLGXDOFKDQJHVLQWKH
IAUC of reference and test meals are significantly different (**** p<0.000005) (panels C and E, 
C = control, J = juice). Average glucose curves after consumption of reference (Ƒ), pomegranate 
capsules containing lower dose (ƔDQGSRPHJUDQDWHFDSVXOHVFRQWDLQLQJKLJKHUGRVHŸPHDOV
for 16 volunteers (panel B). There is no significance difference between IAUC of reference 
meals and test meals at either dose (panels D and F, C = control, D1 = lower dose, D2 = higher 
dose).  
 
 
FIGURE 5. Effect of pomegranate polyphenol gut microbiota metabolites on uptake of sugars in 
human hepatic HepG2 cells. Effect of urolithins and conjugates on uptake of [U-14C]-deoxy-D-
glucose (panel A) and of [U-14C]-glucose (panel B) by HepG2 cells (n = 12, ± SD). Each 
treatment was compared to the control: * p<0.05; ** p<0.01 by independent samples Students t-
test and the 2-tailed values were adjusted for multiple comparisons with the Bonferroni 
correction. Urolithin A, UroA; Urolithin B, UroB; Urolithin C, UroC; Urolithin D, UroD; 
Urolithin A glucuronide, UroAglu; Urolithin B glucuronide, UroBglu; all compounds at 5 PM. 
 
FIGURE 6. Proposed mechanisms of action. Black arrow shows strong site of inhibition of 
bread digestion by punicalagin, which then affects blood glucose postprandially, and light gray 
arrows show possible but weaker points of interaction. Potential of sites of action of metabolites 
of pomegranate polyphenols after the post-prandial period are shown by white arrows. 
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Figure 6.  
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